All In MedTech

Device Trial Radar · NCT06950021

Safety & Performance of CANOpus PINtuition Surgical Marker Navigation

Safety & Performance of CANOpus PINtuition Surgical Marker Navigation (CANOPIN)

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Nov 1, 2025

Study completion Feb 1, 2026

Sponsor

Lead sponsor
Sirius Medical Systems B.V.Not on our public-company list
Sponsor type
Industry
Collaborators
Avania
First posted
Apr 29, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and performance of the Canopus Marker in adult breast cancer patients who are scheduled for breast-conserving surgery. The main questions it aims to answer are: 1. Can the Canopus Marker be safely and effectively used to mark tissue for surgical removal? 2. What is the satisfaction level of radiologists, surgeons, and patients with the use of the Canopus Marker? Participants will: * Have the Canopus Marker implanted into the tumor or nearby tissue using ultrasound guidance. * Undergo surgery where the Canopus Marker will help guide the surgeon to the tumor, and the marker will be removed along with the tumor. This surgery is performed using an FDA cleared and CE-marked detection device (Sirius Pintuition Detector). * Attend a follow-up visit two weeks after surgery to assess any adverse events and overall satisfaction.

Conditions

  • Breast Surgery
  • Lymph Node Excision

Interventions

  • Magnetic seedDevice

    All patients enrolled will receive a single Sirius Canopus Marker with two anchors added to it for improved tissue fixation. Implantation will be done by a radiologist before breast conserving surgery, usually scheduled within a few days after Canopus Marker implantation. The Canopus Marker is removed with the specimen during the surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Performance: Retrieval RateTime frame: From enrolment to the follow-up visit at 2 weeks after surgery (estimated 3-5 weeks)

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rode Kruis Ziekenhuis

    Beverwijk, North Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.